-
1
The study analyzed 376 differentiated thyroid cancer patients who received 100 mCi of adjuvant ¹³¹I therapy after total thyroidectomy.
-
2
The incidence of non-excellent response (nER) among patients was found to be 48.40% at the 6-month follow-up.
-
3
Independent risk factors for nER included BMI, number of metastatic lymph nodes, stimulated thyroglobulin, BRAF mutation, and mean residual ¹³¹I uptake count.
-
4
The random forest predictive model demonstrated the highest performance with an AUC of 90.77%, indicating its effectiveness in predicting treatment response.
-
5
Patients with high stimulated thyroglobulin, multiple lymph node metastases, and elevated BMI had a 100% risk of non-excellent response.
